When we examined the effects of adding targeted therapies, including HDAC and PI3K inhibitors, to PUVA therapy, we found that neratinib, at sub-lethal doses alone, significantly increased apoptosis in ErbB2+ breast cancer cells when combined with PUVA. The gene discussed is ERBB2; the disease is breast cancer.